A concerning trend has emerged in the medical field, highlighting the rising prescription rates of sedatives for seniors, particularly those with dementia. This issue is a cause for alarm, as it raises questions about the appropriate use of antipsychotic medications and their potential risks.
When faced with the challenging behaviors of dementia patients, such as wandering or shouting, it's understandable that families and caregivers seek solutions. However, the reliance on antipsychotic drugs is a controversial approach, especially considering their limited effectiveness for dementia and the serious health risks they pose.
Research conducted by Rutgers and Columbia University reveals a significant increase in antipsychotic prescriptions for older adults in the United States. Despite the black-box warning on these drugs, indicating an increased risk of death for seniors, the annual rate of antipsychotic use has risen by nearly 52% from 2015 to 2024.
The study, led by Stephen Crystal, director of the Center for Health Services Research at Rutgers, found that long-term use of antipsychotics among adults aged 65 and older has also increased by 65% during the same period. This trend is particularly concerning given the limited proven benefits of these medications for this age group and the serious risks they entail, including falls, fractures, and cardiovascular issues.
Antipsychotics may be considered a last resort for managing severe behavioral symptoms of dementia, such as aggression or hallucinations. However, their use should be carefully evaluated and limited to short-term scenarios whenever possible due to the substantial risks involved.
"The evidence on the risks is pretty solid," Crystal emphasized.
The researchers' primary concern lies with the use of antipsychotics to manage the behavioral and psychological symptoms associated with dementia, such as agitation and wandering. In many cases, these medications are prescribed to calm disruptive behaviors, but they come with a high cost for frail patients, increasing the risk of falls and reducing physical activity.
The study also revealed a shift in the management of these cases. The involvement of psychiatrists in prescribing antipsychotics has declined, while the use of long-term care facility pharmacies for these prescriptions has increased. This shift raises questions about the careful evaluation and diagnosis process, which is crucial for optimal care.
Crystal highlighted the importance of confirming diagnoses and exploring treatable causes that may mimic or worsen confusion, such as medication interactions or underlying health issues. Non-drug approaches can be effective, but they require adequate training, staffing, and time, which are often lacking in nursing homes and assisted living facilities.
"It's easier to write a prescription than address the underlying condition," Crystal noted.
While the decline in first-generation antipsychotic use, which carries a higher mortality risk for older patients, is a positive sign, the overall increase in antipsychotic prescriptions suggests a reliance on medication to address complex social, environmental, and staffing-related issues.
The authors of the study call for a renewed focus on evaluating and implementing non-pharmacological interventions to reduce the need for antipsychotics in older adults.
For families facing new prescriptions, Mark Olfson, the study's lead author, recommends questioning the purpose of the medication and exploring alternative steps. It's crucial to have a plan for reassessing and potentially tapering off the medication once the crisis has passed.
"These decisions carry high stakes," Olfson emphasized.
The study's authors, including Fangzhou Xie, Greta Bushnell, Jialiang Hua, and Jennifer Miles, all from Rutgers University, have shed light on a critical issue that warrants further discussion and action.
